Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: The case study of Japan-Reference-Cited by-同舟云学术

Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: The case study of Japan

Published:2016-05-12 Issue:9 Volume:19 Page:889-899
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Hori Masatsugu¹,Ikeda Shunya²,Okumura Ken³,Matsuda Shinya⁴,Koretsune Yukihiro⁵,Montouchet Calypso⁶,Watanabe-Fujinuma Emi⁷,Evers Thomas⁸,Rossi Bruno⁷,Ruff Lewis⁶,Briere Jean-Baptiste⁸

Affiliation:

1. Osaka Medical Centre for Cancer and Cardiovascular Diseases, Osaka, Japan;

2. International University of Health and Welfare, Otawara, Japan;

3. Hirosaki University, Hirosaki, Japan;

4. University of Occupational and Environmental Health, Kitakyushu, Japan;

5. Osaka National Hospital, Osaka, Japan;

6. Covance Market Access, London, UK;

7. Bayer Yakuhin, Ltd., Tokyo, Japan;

8. Bayer Pharma AG, Berlin, Germany

Funder

Bayer AG

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2016.1182919

Reference70 articles.

1. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates 11Reprints are not available.

2. Current status of clinical background of patients with atrial fibrillation in a community-based survey: The Fushimi AF Registry

3. National Institute of Population and Social Security Research. Japanese population in 2010 by age and gender. http://www.ipss.go.jp/. Accessed March 2015

4. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study

5. Prevalence of atrial fibrillation in the general population of Japan: An analysis based on periodic health examination

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The budget impact of implementing atrial fibrillation-screening in European countries;European Heart Journal Supplements;2024-07

2. Rivaroxaban concentrations in acute stroke patients with different dosage forms;PLOS ONE;2019-03-21